- Home
- AGIO vs IAUX Comparison
AGIO vs IAUX Comparison
Compare AGIO & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | IAUX |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGIO | IAUX |
|---|---|---|
| Price | $27.95 | $1.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $36.63 | $1.50 |
| AVG Volume (30 Days) | 881.5K | ★ 10.9M |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $54,028,000.00 | ★ $97,131,000.00 |
| Revenue This Year | $104.62 | $85.81 |
| Revenue Next Year | $125.15 | $97.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 48.03 | ★ 83.46 |
| 52 Week Low | $22.24 | $0.48 |
| 52 Week High | $46.00 | $2.24 |
Technical Indicators
Market Signals| Indicator | AGIO | IAUX |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 60.46 |
| Support Level | $26.05 | $1.68 |
| Resistance Level | $29.93 | $2.24 |
| Average True Range (ATR) | 1.18 | 0.14 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 62.47 | 60.45 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.